As Pfizer Taps Established Products Chief To Lead Emerging Markets, Is Consolidation Of Its Business Units Imminent?
This article was originally published in The Pink Sheet Daily
Executive Summary
The appointment of David Simmons to run a second business unit could foretell the union of the two divisions as part of a larger restructuring.
You may also be interested in...
In Pfizer Business Review, Established Products Unit Is Most "Complex," Simmons Says
With Pfizer Inc. in the midst of a strategic business review that includes an evaluation of all business units outside the "innovative core," even the company's Established Products business unit - made up of mature pharmaceuticals that have lost exclusivity in developed markets - could be spun out or put up for sale
In Pfizer Business Review, Established Products Unit Is Most "Complex," Simmons Says
President of Emerging Markets and Established Products David Simmons offers a glimpse into how Pfizer's strategic business review is progressing.
In Pfizer Business Review, Established Products Unit Is Most "Complex," Simmons Says
President of Emerging Markets and Established Products David Simmons offers a glimpse into how Pfizer's strategic business review is progressing.